Patent Expiry Impact Predictor
Journal of Generic Medicines (2006) 4, 73–78. doi:10.1057/palgrave.jgm.4950048
Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years
Compiled and written by Datamonitor plc
Datamonitor plc (DTML) is a premium business information company specialising in industry analysis and providing clients with unbiased expert analysis and in-depth forecasts for six industry sectors:
Automotive
Consumer markets
Energy
Financial services
Healthcare
Technology
No part of this section may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the author, Datamonitor plc. The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, Datamonitor can accept no liability whatever, for actions taken based on any information that may subsequently prove to be incorrect. Please contact:
Joanna Chertkow
Datamonitor plc
Charles House
108–110 Finchley Road
London
NW3 5JJ
UK
Datamonitor maintains its headquarters in London and has regional offices in New York, Frankfurt and Hong Kong.
Duncan Emerton1
1is a senior analyst in Datamonitor's Cardiovascular team.
